ArticleRedox biology2026
ReDisulphID: A discovery platform for thiol redox sensors identifies a druggable site regulating p53 activation.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thiol redox sensors in proteins are emerging as key therapeutic targets, as they govern fundamental signalling pathways and provide crucial sites for covalent drug development. A key mediator of their function is the presence of redox-active disulphides, which act as molecular switches due to their ability to induce reversible protein conformational changes. However, despite their importance in cellular regulation and therapeutic relevance, only a limited number of redox-active disulphides have been identified to date. To address this, we developed ReDisulphID, a structural bioinformatics platform that systematically identifies druggable redox-active disulphides. Using this platform, we discovered novel druggable redox sensors in MLYCD, TFIIB, and PEPD. Functional analysis of PEPD revealed that its redox sensor activates the tumour suppressor p53. Furthermore, we identified a compound that activates p53 through direct thiol modification of the sensor in PEPD, demonstrating how ReDisulphID can advance the discovery of protein redox sensors and support thiol-targeted drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.